Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
about
Big Data Offers Novel Insights for Oncolytic Virus ImmunotherapyAntigen-specific T cells fully conserve antitumour function following cryopreservation.CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysisMucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory studyImmunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients.PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor CellsNext Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation.Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancerProgramming the immune checkpoint to treat hematologic malignancies.Efficacy of adoptive cellular therapy in patients with gastric cancer: a meta-analysis.The Therapeutic Potential of Targeting Tumor Microenvironment in Breast Cancer: Rational Strategies and Recent Progress.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.IL-10: Expanding the Immune Oncology Horizon.NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes.Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment.SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy.Adaptive Resistance to Cancer Immunotherapy.Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.SOCS1: Regulator of T Cells in Autoimmunity and Cancer.
P2860
Q26767209-EB37DC6C-4BAE-46F4-8CA9-FDB96AE89D03Q27323082-629AC876-FDF4-4E8A-90F3-CB38F545AE4BQ35655089-633F469C-1349-4300-9BD1-BC79BEBDBAF8Q35886589-4CFD6BEC-F2E6-4215-8FA4-DA5FC97DFCA9Q36059250-AD052E6A-71E4-45A5-BA1A-036CEB024885Q36657043-6068A634-A2E5-4E08-BE19-C5260D372FB4Q36664258-5EA8A590-A3C0-400D-9548-AAD239F53024Q36757142-460902D0-37E2-45F1-B2FD-DFCD7C80FCC0Q36854062-398793A2-F934-4821-B397-4FBBB4FE9399Q36936564-E8E7E0B9-DCD5-41A9-B943-193D8EBAE333Q37137924-91897505-6486-4308-9A13-B5B1F7741749Q37214957-B9E1AA96-C510-48E3-89A0-16C345898BA3Q37320156-3594AB81-6F78-4429-AEA4-252AE463B538Q37486166-7B6B23E4-1B0B-4030-AC29-6ED714DFDD83Q37554202-7EEA3EEC-5A54-4D22-8779-7D0F756187A0Q37612527-428A6B13-4E84-4AE6-8EC1-C8A1660D9E82Q38644119-14D20090-9828-4C22-99D4-3570028AE186Q38806070-EA910AA4-DA2D-4D04-AAB2-9863507453FCQ38887317-692D2170-4721-4DC8-993D-09EC3E5B8BB8Q39346175-5C6ED8A2-8D25-4921-AC61-C54B3BC3EFBAQ40188258-D82DA1AF-A4FC-4BE4-A9CB-E2D59CAAE1F7Q40217856-97D29009-0096-42A5-8CDC-074A27FC47FBQ40595500-CE521E71-8245-40EB-B085-6D99355E5F00Q41201828-2CA1F747-266C-46DA-9598-AAD20B95A66EQ41607185-C8FB786D-766C-4C11-8DD0-23884B9BD21FQ41939949-3F4A214A-FC14-451B-AA64-61151316A27FQ47174541-E3FCCD90-0673-4479-B94E-6294967480BFQ47252744-0AA607FE-477A-474C-934F-FCEDB96B674BQ48505173-60BD3353-9AB8-43F1-AA1E-C081F7059161Q50125557-AB617C54-66FC-400D-B3A8-E60B224A2712
P2860
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@en
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@nl
type
label
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@en
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@nl
prefLabel
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@en
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
@nl
P2093
P2860
P356
P1433
P1476
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor
@en
P2093
A J Robert McGray
Arthur A Hurwitz
Dannie Bernard
Florentina Teoderascu
John A Hassell
Robin Hallett
Stephanie L Swift
Yonghong Wan
Ziqiang Zhu
P2860
P304
P356
10.1038/MT.2013.255
P577
2013-10-23T00:00:00Z